Retrospective observational study for the risk of hepatitis B virus reactivation in patients with T-cell lymphoma who received mogamulizumab-containing chemotherapy
Not Applicable
Recruiting
- Conditions
- T-cell lymphoma patients with HBsAg-positive or resolved HBV infection
- Registration Number
- JPRN-UMIN000048047
- Lead Sponsor
- Kumamoto University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria
Not provided
Exclusion Criteria
1)Patients with seropositive for anti-HCV. Patients without measurement for ant-HCV were eligible. 2)Patients with seropositive for anti-HIV. Patients without measurement for ant-HIV were eligible.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Incidence of HBV reactivation
- Secondary Outcome Measures
Name Time Method Incidence of hepatitis and severity of hepatitis (requiring systemic steroids) Incidence of HBV reactivation-related hepatitis Incidence of HBV reactivation-related fulminant hepatitis Incidence of HBV reactivation-related mortality Incidence of decompensated liver cirrhosis (if patients with HBsAg-positive) Incidence of hepatocellular carcinoma (if patients with HBsAg-positive) Incidence of hepatocellular carcinoma-related mortality (if patients with HBsAg-positive) Incidence of anti-HBV prophylaxis using nucleoside/nucleotide analogues (if patients with HBsAg-positive) Incidence of anti-HBV treatment using nucleoside/nucleotide analogues (if patients with resolved HBV infection) Overall survival